The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.

Oncogene
Daniel GerlachNorbert Kraut

Abstract

Bromodomain and extra-terminal (BET) protein inhibitors have been reported as treatment options for acute myeloid leukemia (AML) in preclinical models and are currently being evaluated in clinical trials. This work presents a novel potent and selective BET inhibitor (BI 894999), which has recently entered clinical trials (NCT02516553). In preclinical studies, this compound is highly active in AML cell lines, primary patient samples, and xenografts. HEXIM1 is described as an excellent pharmacodynamic biomarker for target engagement in tumors as well as in blood. Mechanistic studies show that BI 894999 targets super-enhancer-regulated oncogenes and other lineage-specific factors, which are involved in the maintenance of the disease state. BI 894999 is active as monotherapy in AML xenografts, and in addition leads to strongly enhanced antitumor effects in combination with CDK9 inhibitors. This treatment combination results in a marked decrease of global p-Ser2 RNA polymerase II levels and leads to rapid induction of apoptosis in vitro and in vivo. Together, these data provide a strong rationale for the clinical evaluation of BI 894999 in AML.

References

Apr 5, 2007·Nature Protocols·Tong Ihn LeeRichard A Young
Jun 3, 2008·Current Opinion in Cell Biology·Vanessa BrèsKatherine A Jones
Sep 28, 2010·Nature·Panagis FilippakopoulosJames E Bradner
Aug 5, 2011·Nature·Johannes ZuberChristopher R Vakoc
Sep 6, 2011·Cell·Jake E DelmoreConstantine S Mitsiades
Oct 23, 2012·The Journal of Biological Chemistry·Weishi ZhangKeh-Chuang Chin
Oct 15, 2013·Cell·Denes HniszRichard A Young
Jun 7, 2014·Molecular Cell·Hariharan EaswaranStephen B Baylin
Jun 7, 2014·Molecular Cell·Junwei Shi, Christopher R Vakoc
Jul 22, 2014·British Journal of Pharmacology·Laia Simó-Riudalbas, Manel Esteller
Jul 23, 2014·Proceedings of the National Academy of Sciences of the United States of America·Michele CeribelliLouis M Staudt
Nov 11, 2014·Nature Structural & Molecular Biology·Tomohiko KannoKeiko Ozato
Dec 31, 2014·Nature Genetics·Sebastian Pott, Jason D Lieb
Jan 13, 2015·The Journal of Pharmacology and Experimental Therapeutics·Dorothea RudolphNorbert Kraut
Jan 28, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michela BoiFrancesco Bertoni
Feb 19, 2015·Nature Reviews. Molecular Cell Biology·Iris Jonkers, John T Lis
May 21, 2015·Oncotarget·Marie-Magdelaine CoudéClaude Gardin
Jun 17, 2015·Epigenomics·Marie JungBernard Haendler
Sep 15, 2015·Nature·Chun Yew FongMark A Dawson
Dec 4, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anton HenssenJohannes H Schulte
Jan 7, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeyran ShahbaziTao Liu
Jan 23, 2016·Molecular Cell·Roland SchüllerDirk Eick
Apr 12, 2016·The Lancet. Haematology·Céline BerthonHervé Dombret
Jul 9, 2016·International Journal of Cancer. Journal International Du Cancer·Caroline Berenguer-DaizéL'Houcine Ouafik
Jul 12, 2016·Cell·Francesco IorioMathew J Garnett

❮ Previous
Next ❯

Citations

Aug 2, 2018·Cellular and Molecular Life Sciences : CMLS·Jianbiao ZhouWee-Joo Chng
Jul 20, 2018·Journal of Virology·C David WoodMichelle J West
Nov 10, 2018·Transcription·Matthew D GalbraithJoaquín M Espinosa
Apr 12, 2019·Heart Failure Reviews·Rachel A MinerathChad E Grueter
May 10, 2019·Cancers·Feda H Hamdan, Steven A Johnsen
Jun 20, 2019·Cancers·Mélanie LambertMarie-Hélène David-Cordonnier
Oct 12, 2019·Nature Reviews. Drug Discovery·Soufiane Boumahdi, Frederic J de Sauvage
Jan 24, 2020·Blood Advances·Hannah McCalmontRichard J D'Andrea
May 10, 2020·Experimental & Molecular Medicine·Qunying JiaFaqing Tang
Jul 10, 2018·Oncotarget·Alexandra HörmannRalph A Neumüller
Oct 7, 2018·Journal of Mammary Gland Biology and Neoplasia·Kyung Hyun YooHa Youn Shin
Aug 9, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Brittany L Allen-Petersen, Rosalie C Sears
Feb 16, 2019·Nature Reviews. Urology·Sina JostesHubert Schorle
Jan 11, 2020·Frontiers in Oncology·Raoul Tibes, James M Bogenberger
Jul 18, 2019·Journal of Hematology & Oncology·Yunlu JiaJianbiao Zhou
May 21, 2019·Frontiers in Pharmacology·Yi HeQing Liu
Dec 17, 2020·International Journal of Molecular Sciences·Jessica McAnulty, Analisa DiFeo
Jan 14, 2020·Pharmacology & Therapeutics·Oliver Bechter, Patrick Schöffski
May 25, 2021·Genesis : the Journal of Genetics and Development·Shibai XiaoMin Yang
Jun 3, 2021·Cancers·Ranadip MandalKlaus Strebhardt
Jun 10, 2021·Neoplasia : an International Journal for Oncology Research·Joanna S YiW Clay Gustafson
Jul 25, 2021·International Journal of Molecular Sciences·Alvina I KhamidullinaAlexandra V Bruter
Aug 11, 2021·Journal of Hematology & Oncology·Seyed Esmaeil AhmadiMajid Safa
Mar 11, 2021·Cardiovascular & Hematological Disorders Drug Targets·Ota Fuchs, Radka Bokorova

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE101821

Methods Mentioned

BETA
xenograft
xenografts
immunoprecipitation
ChIP-seq
RNA-seq
AlphaLISA
ChIP

Clinical Trials Mentioned

NCT02520011
NCT02516553

Software Mentioned

Bedtools
R
MACS
bowtie2
BROMO
BETi
TREE spot TM
MSigDB
GSEA
HOMER

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.